Showing 4821-4830 of 21484 results for "".
- Marie Claire Recognizes ZORYVE for Atopic Dermatitis Treatmenthttps://reachmd.com/news/marie-claire-recognizes-zoryve-for-atopic-dermatitis-treatment/2488632/Arcutis Biotherapeutics announced that roflumilast cream 0.15% (ZORYVE) received Marie Claire’s inaugural 2026 Best Prescription Skin Solution Award, a new category recognizing innovation in prescription dermatologic treatments. The award recognizes ZORYVE f
- Tozorakimab Cut COPD Exacerbations in OBERON and TITANIAhttps://reachmd.com/news/tozorakimab-cut-copd-exacerbations-in-oberon-and-titania/2488614/Key Takeaways Among former smokers with chronic obstructive pulmonary disease (COPD) and previous exacerbations despite stable inhaled maintenance therapy, add-on tozorakimab significantly lowered annualized moderate or severe exacerbation rates versus placebo in both trials.
- Race, Stroke Belt, and Cerebral Microbleeds After Strokehttps://reachmd.com/news/race-stroke-belt-and-cerebral-microbleeds-after-stroke/2488617/Key Takeaways Among REGARDS participants with incident stroke or TIA and available MRI, Black participants had higher adjusted odds of any CMB. Stroke-belt residents had lower adjusted odds of any, non-lobar, and lobar CMBs and a lower modeled CMB count. Bla
- Environmental Exposures, Skin Barrier Care Take Focus in Pediatric AD Consensushttps://reachmd.com/news/environmental-exposures-skin-barrier-care-take-focus-in-pediatric-ad-consensus/2488624/Environmental exposures early in childhood that affect the skin barrier may contribute to the development of atopic dermatitis, and impact its severity, according to a new expert consensus published in the Journal of Drugs in Dermatology. The SAIGE III report examined current evid
- Dr. Shawn Kwatra Analyzes ADtouch Data on Hand and Foot Atopic Dermatitishttps://reachmd.com/news/dr-shawn-kwatra-analyzes-adtouch-data-on-hand-and-foot-atopic-dermatitis/2488634/New Phase 3b ADtouch data for lebrikizumab-lbkz (Ebglyss; Eli Lilly and Company) may help broaden how dermatologists assess disease burden in patients with atopic dermatitis (AD) affecting high-impact areas, according to study investigator Shawn Kwatra, MD.
- Litifilimab Meets Primary Endpoint in Phase 2 Cutaneous Lupus Studyhttps://reachmd.com/news/litifilimab-meets-primary-endpoint-in-phase-2-cutaneous-lupus-study/2488613/Biogen reported positive phase 2 results from Part A of the phase 2/3 AMETHYST study evaluating litifilimab in patients with cutaneous lupus erythematosus (CLE), with the investigational therapy meeting the study’s primary endpoint and showing improvement across several mea
- Dr. Alexa Kimball Highlights Early Response, HiSCR75 Findings With Tulisokibart in Hidradenitis Suppurativahttps://reachmd.com/news/dr-alexa-kimball-highlights-early-response-hiscr75-findings-with-tulisokibart-in-hidradenitis-suppurativa/2488609/New Phase 2b data for tulisokibart may provide early clinical evidence supporting tumor necrosis factor-like cytokine 1A (TL1A) as a therapeutic target in hidradenitis suppurativa (HS), according to study investigator Alexa Kimball, MD, MPH.
- Sun Pharma Reports 2-Year Deuruxolitinib Data in Severe Alopecia Areatahttps://reachmd.com/news/sun-pharma-reports-2-year-deuruxolitinib-data-in-severe-alopecia-areata/2488607/Long-term treatment with deuruxolitinib (LEQSELVI, Sun Pharmaceutical Industries Limited) showed sustained scalp hair response through Week 108 among selected responders with severe alopecia areata (AA), according to open-label extension (OLE) data presented at the 2026 European Academy of Dermat
- Delgocitinib Shows Real-World and Adolescent CHE Outcomes: Studyhttps://reachmd.com/news/eadv-2026-delgocitinib-shows-real-world-and-adolescent-che-outcomes/2488596/LEO Pharma presented new delgocitinib cream data at the 35th European Academy of Dermatology and Venereology (EADV) Congress, including interim real-world findings in adults and post hoc phase 3 analyses examining symptoms and quality of life in adolescents with moderate to
- Parkinson's AI Chatbot Misses Critical Safety Errorshttps://reachmd.com/news/parkinsons-ai-chatbot-safety-errors/2488601/Key Takeaways In Germany, a publicly deployed Parkinson's disease information chatbot showed mostly favorable automated triage during its first 129 days, with 88.6% of conversations rated good, 11% partially adequate, and 0.4% inadequate. Expert review of conversatio